Neurocrine Biosciences
NBIX
732 hedge funds and large institutions have $14.1B invested in Neurocrine Biosciences in 2025 Q4 according to their latest regulatory filings, with 139 funds opening new positions, 279 increasing their positions, 220 reducing their positions, and 41 closing their positions.
239% more first-time investments, than exits
New positions opened: 139 | Existing positions closed: 41
27% more repeat investments, than reductions
Existing positions increased: 279 | Existing positions reduced: 220
13% more funds holding
Funds holding: 650 → 732 (+82)
1.47% more ownership
Funds ownership: 98.01% → 99.49% (+1.5%)
3% more capital invested
Capital invested by funds: $13.6B → $14.1B (+$427M)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
42% less call options, than puts
Call options by funds: $41.3M | Put options by funds: $71.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$101M |
| 2 |
Two Sigma Investments
New York
|
+$92.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$89.7M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$72.2M |
| 5 |
JP Morgan Chase
New York
|
+$68.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$144M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$103M |
| 3 |
Morgan Stanley
New York
|
-$89.5M |
| 4 |
Millennium Management
New York
|
-$77.4M |
| 5 |
Jennison Associates
New York
|
-$73M |
NBIX Hedge Fund Activity: Q4 2025 in Review
732 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2025, worth a combined $14.1B — up 3.1% from $13.6B a quarter earlier.
Buyers outnumbered sellers: 139 funds opened new NBIX positions and 41 closed out — a net gain of 98 holders — while 279 added to existing stakes and 220 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $101M. The largest seller was T. Rowe Price Associates, cutting an estimated $144M.
- 732 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2025, up from 650 in Q3 2025.
- Funds reported $14.1B of Neurocrine Biosciences stock for Q4 2025, up 3.1% quarter-over-quarter.
- 139 funds opened new Neurocrine Biosciences positions in Q4 2025 and 41 closed out, a net change of +98 holders.
- The largest Neurocrine Biosciences buyer in Q4 2025 was Two Sigma Advisers, an estimated $101M added.
- The largest Neurocrine Biosciences seller in Q4 2025 was T. Rowe Price Associates, an estimated $144M sold.
Based on aggregated 13F filings for Q4 2025.